IMHO... nobody's shorting this stock... at least not any more... and they haven't for a while... it's far too thinly traded... and has been for many months. The problem with MFYS was that it over-promised and under-delivered. Expected revenues are over a year late and pinks get KILLED if they fail to deliver results for very long.
The GOOD NEWS is, MFYS finally has inked some contracts and has committed revenues for Sept 1 and beyond. Yes... it's modest compared to what was expected last year, but Medify is now a 11 cent stock (as opposed to $1.00+) and even modest revenues get handsomely rewarded at this low pps.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.